Rubius Therapeutics Inc (NASDAQ:RUBY) – Investment analysts at Jefferies Financial Group dropped their FY2020 EPS estimates for shares of Rubius Therapeutics in a report released on Sunday, March 8th. Jefferies Financial Group analyst M. Yee now forecasts that the company will post earnings of ($2.90) per share for the year, down from their prior estimate of ($2.79). Jefferies Financial Group also issued estimates for Rubius Therapeutics’ Q4 2020 earnings at ($0.80) EPS and FY2021 earnings at ($3.13) EPS.
Several other equities research analysts also recently commented on RUBY. Zacks Investment Research downgraded Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. BidaskClub upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 26th. JPMorgan Chase & Co. downgraded Rubius Therapeutics from an “overweight” rating to a “neutral” rating and set a $9.00 price objective for the company. in a report on Friday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Rubius Therapeutics in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Rubius Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $17.40.
NASDAQ RUBY opened at $6.55 on Wednesday. Rubius Therapeutics has a one year low of $6.36 and a one year high of $20.04. The stock has a 50-day moving average of $8.16 and a 200 day moving average of $9.18. The company has a market capitalization of $621.65 million, a price-to-earnings ratio of -3.52 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a quick ratio of 9.83 and a current ratio of 9.83.
In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 48,000 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $13.48, for a total transaction of $647,040.00. Following the completion of the sale, the insider now directly owns 82,843 shares in the company, valued at approximately $1,116,723.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 58.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in RUBY. Bank of Montreal Can grew its stake in shares of Rubius Therapeutics by 45.0% during the 4th quarter. Bank of Montreal Can now owns 4,437 shares of the company’s stock valued at $42,000 after purchasing an additional 1,377 shares during the period. NEXT Financial Group Inc bought a new stake in shares of Rubius Therapeutics during the 4th quarter valued at about $60,000. Tower Research Capital LLC TRC grew its stake in shares of Rubius Therapeutics by 650.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,722 shares of the company’s stock valued at $64,000 after purchasing an additional 5,826 shares during the period. Virtu Financial LLC bought a new stake in shares of Rubius Therapeutics during the 4th quarter valued at about $106,000. Finally, Marshall Wace LLP bought a new stake in shares of Rubius Therapeutics during the 4th quarter valued at about $111,000.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.